The Future of the Global Infectious Disease Booster Market
Vakston is creating novel responses to infectious diseases and is committed to bringing vaccines to patients across the world. Vakston leverages its first-in-class Ambifect™ Fc-fusion platform to provide accessible, durable vaccines and boosters that improve human health.
Ambifect™ Vaccine Fc-fusion Platform Advantages
The Ambifect™ Fc-fusion Platform has the capability to spearhead the next generation of globally accessible vaccines due to its disruptive competitive advantages:
- Lowest cost – pennies per dose to manufacture
- Reduced development time and cost
- No cold chain restrictions – shelf stable for > 6 months
- Versatile and customizable – enables pipeline expansion in therapeutic vaccines
- First-in-class tolerance and efficacy
- Best-in-class booster across new variants, long-lasting durable neutralizing immune response
Current pipeline indications in development or under consideration include: COVID-19, RSV, MERS, Multivalent URTls, Infectious Diseases.